Former Chief Executive Officer and Director at Mylan N.V.
Heather Bresch Chief Executive Officer Executive Director Committee membership: Science and Technology Heather Bresch was elected to the board of directors of Mylan in 2011. She is a member of Mylan’s Science and Technology Committee. Bresch has served as Mylan’s CEO since January 1, 2012. Throughout her 28-year career with Mylan, Bresch has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, Bresch served as the company’s president, where she was responsible for its day-to-day operations. Before that, she served as chief operating officer and chief integration officer, leading the successful integration of two international acquisitions – Matrix Laboratories and Merck KGaA’s generics business – which more than doubled Mylan’s size and transformed it from a purely U.S. company to a global one. As CEO, Bresch has been leading the latest chapter of Mylan’s growth and performance, pursuing a strategy that has produced a sustainable organization that is making great strides in its mission of delivering better health for a better world by providing 7 billion people access to high quality medicine. In continuing to execute on this strategy, Bresch is focused on further diversifying the company in terms of products, markets and channels, a process proven to expand access and generate durable cash flows that can be reinvested to further differentiate Mylan and position it to support the transformation of outdated healthcare systems. To achieve Mylan’s goals, Bresch emphasizes a collaborative company culture focused on leading, learning, teaching and performing to inspire innovation and help set new standards in healthcare. She also remains a vocal champion of initiatives and policy changes aimed at removing access barriers. Among her policy priorities is increasing generic utilization, driving biosimilars interchangeability, stemming the tide of HIV/AIDS, ensuring a fair and a level competitive playing field, and strengthening the global supply chain to make it safer. Bresch is a frequent speaker on issues such as affordable healthcare and global competitiveness and has testified before the U.S. Congress and the U.S. Food and Drug Administration on issues related to access to medicine. Bresch is the pharmaceutical industry’s first female chief executive officer of a Fortune 500 company and was previously named by Fortune magazine as one of its “50 Most Powerful Women.” In July 2019, Mylan announced a definitive agreement to combine with Upjohn, a division of Pfizer, creating a new champion for global health. Bresch also announced her retirement as CEO and board member upon closing, which is anticipated for 2020. The transaction represents the culmination of Bresch’s goals to set new standards in healthcare. As Mylan sets out on a new journey, Bresch, too, will begin a new chapter that will continue to be focused on serving people, patients and public health. Meet Heather
Source: Mylan N.V. on 11/26/2020
By accessing ExecAtlas, you can view bios, network, connections and references of industry leading executives like Heather M. Bresch. More specifically, you'll be able to:
Access over 1,500,000 executive and board member profiles.
Example: Heather M. Bresch